This matters for this comparison because Ros published Ro Body Program materials reference 15% average body weight reduction at week 68 a figure from the STEP clinical trial program, which studied branded Wegovy, not compounded semaglutide
*Before and after images reflect real patient results, although individual results may vary
We do not charge you more for succeeding in your titration plan
Research is continuously investigating new multi-receptor agonists that may provide improved therapeutic advantages while ensuring acceptable safety profiles
Adzynma, a purified recombinant form of this enzyme, provides a replacement for the low levels of the deficient enzyme in patients with cTTP
The New Pharmaceutical Imperative With strong evidence suggesting systemic benefits far beyond glycemic control and weight managementincluding cardiovascular protection and effects on inflammationGLP-1s are now viewed as foundational longevity therapeutics